GRI Bio, Inc. current report, 26 February 2021

Full document

SEC Form 8-K Summary

Business Context and Reporting Period

The filing is a Current Report on Form 8-K filed by Vallon Pharmaceuticals, Inc. on February 26, 2021. The filing does not present quarterly or annual financial results; it reports the furnishing of an updated corporate presentation.

Note: The request metadata identifies GRI Bio, Inc., but the filing text identifies Vallon Pharmaceuticals, Inc. as the registrant.

Financial and Operating Metrics

The filing text does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. No financial statements are included.

Material Changes Versus the Prior Comparable Period

No period-over-period financial or operating comparison is provided. The only reported development is the availability of an updated corporate presentation dated February 2021.

Guidance, Outlook, Risks, and Unusual Items

  • The updated corporate presentation was furnished as Exhibit 99.1 and was also expected to be available on the Company’s website.
  • The presentation itself is not included in the supplied filing text, so any guidance, pipeline updates, clinical information, risks, or management commentary cannot be evaluated from this document alone.
  • The information, including Exhibit 99.1, was furnished under Regulation FD and was not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
  • The Company stated that it undertakes no obligation to publicly update or revise the information.

Important Facts for Investors to Verify

  • Confirm the correct issuer, because the supplied filing names Vallon Pharmaceuticals, Inc., while the request identifies GRI Bio, Inc.
  • Review Exhibit 99.1, the February 2021 corporate presentation, for the substantive business, clinical, financial, and outlook information.
  • Check subsequent SEC filings for updated financial condition, financing needs, clinical developments, and risk disclosures.
  • The filing identifies common stock trading under the symbol VLON on the Nasdaq Capital Market.